Pleuropulmonary and Lymph Node Progression after Docetaxel - Benefits from Treatment with Cabazitaxel in Metastatic Prostate Cancer

Publisher： Karger

E-ISSN： 1662-6575|6|2|391-396

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.6, Iss.2, 2013-07, pp. : 391-396

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study

By  

Oncology, Vol. 92, Iss. 2, 2016-12 ,pp. : 94-100

Karger

Access to resources Recommend Favorite

Clinical benefits of non‐taxane chemotherapies in unselected patients with symptomatic metastatic castration‐resistant prostate cancer after docetaxel: the GETUG‐P02 study

By  

BJU INTERNATIONAL, Vol. 115, Iss. 1, 2015-01 ,pp. : 65-73

John Wiley & Sons Inc

Access to resources Recommend Favorite

Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer

By  

Reviews on Recent Clinical Trials, Vol. 11, Iss. 4, 2016-10 ,pp. : 317-323

Bentham Science Publishers

Access to resources Recommend Favorite

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre

By  

Case Reports in Oncology, Vol. 9, Iss. 2, 2016-08 ,pp. : 506-515

Karger

Access to resources Recommend Favorite

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 968-975

John Wiley & Sons Inc

Access to resources Recommend Favorite